| 1 | Inhibition of hepatitis B virus by oxymatrine in vivo显示文摘AIM To investigate the anti-HBV effect ofoxymatrine (oxy) in vivo.METHODS HBV transgenic mice were producedby micro-injection of a 4.2kb fragmentcontaining the complete HBV genomes.Expression level of HBsAg and HBcAg in thetransgenic mice liver was determined byimmunohistochemical assay.RESULTS Four groups (6 mice in each group)were injected intraperitoneally with oxy at thedosage of 100,200, and 300 mg/kg or with salineonce a day for 30 days. Both HBsAg and HBcAgwere positive in livers of all the six mice in thecontrol group (injected with saline), and werepositive in livers of two mice in 100 mg/kg groupand 300mg/kg group. In 200mg/kg group,HBsAg and HBcAg were negative in livers of allthe six mice. Based on the results, 200 mg/kg isthe ideal dosage to explore the effect of oxy atdifferent time points. According to the oxytreatment time, mice were divided into fourgroups: 10 d, 20 d, 30 d and 60 d (4 mice in eachgroup). Each mouse underwent liver biopsy twoweeks before the treatment of oxy. Down-regulation of HBsAg and HBcAg appeared aftertreatment of oxymatrine for 10 d and 20 d, Dane-like particles disappeared after the treatment ofoxy for 20d under electron microscopy,however, the expression level of HBsAg andHBcAg returned to normal 60 d later after oxytreatment.CONCLUSION oxymatrine can reduce thecontents of HBsAg and HBcAg in transgenic miceliver, longer treatment time and larger dosagedo not yield better effects. | Xiao Song Chen1 Guo Jun Wang1 Xiong Cai1 Hong Yu Yu2 Yi Ping Hu3 1Department of Infectious Diseases, Changzheng Hospital, the Second Military Medical University, Shanghai 200003, China2Department of Pathology, 3Department of Cell Biology, Department of Basic Medicine, the Second Military Medical University, Shanghai 200433, China | 2001 | World Journal of Gastroenterology2001，7，1： | 13 |
| 2 | Saikosaponin v-2 from Bupleurum chinense显示文摘Saikosaponin v-2(1), was isolated from the roots of the title plant and the structure was identified on the basis of spectral analysis. Saikosaponin v-2 is a new compound, which was identified as 3(,16(,23,28-tetrahydroxy-olean-11,13(18)-dien-30-oic acid-3-O-(-D-glucopyrano- syl-(1?2)glucopyranosyl-(1?3)-(-D-fucopyranosyl-30-O-xylitol ester. | Hong LIANG1, Yan Jun CUI1, Yu Ying ZHAO1*, Bin WANG1, Wen Xiu YANG2, Yi YU2 1Department of Natural Medicines, Peking University, Beijing 100083 2Department of Biophysical Science and Technology, Tianjin university, Tianjin 300071 | 2001 | Chinese Chemical Letters2001，12，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员